Premium
Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment
Author(s) -
Pyun Jung Min,
Park Young Ho,
Lee KeonJoo,
Kim Sangyun,
Saykin Andrew J.,
Nho Kwangsik
Publication year - 2021
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.051524
Subject(s) - apolipoprotein e , dementia , hazard ratio , medicine , alzheimer's disease neuroimaging initiative , proportional hazards model , oncology , single nucleotide polymorphism , allele , psychology , confidence interval , disease , genotype , biology , genetics , gene
Background The combinatorial effect of multiple genetic factors calculated as a polygenic risk score (PRS) has been studied to predict Alzheimer’s disease (AD) risk and evidence suggests that the predictability of PRS can be affected by the presence of APOE e4 allele substantially. Therefore, we aimed to evaluate the predictability of PRS on disease progression to AD depending on APOE ε4 carrier status and its interaction with APOE ε4 in mild cognitive impairment (MCI). Method We analyzed 732 MCI patients from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort with those who progressed to AD within 5 years post‐baseline (n=270) and remained stable as MCI (n=462). The predictability of PRSs including and excluding the APOE region (PRS + APOE and PRS ‐ APOE ) on the conversion to AD and its interaction with APOE ε4 carrier status were assessed using Cox regression analyses. Gene set enrichment analysis of single nucleotide polymorphisms (SNPs) selected for PRS calculation was performed. Result PRS + APOE (hazard ratio (HR) 1.468, 95% CI 1.335–1.615) and PRS ‐ APOE (HR 1.293, 95% CI 1.157–1.445) both were associated with a significantly increased risk of progression to dementia in MCI (Table 1). The interaction between PRS + APOE and APOE ε4 carrier status was significant with a p‐value of 3.78×10 ‐2 (Table 2). The association of PRSs with progression risk was stronger in APOE ε4 non‐carriers (PRS + APOE : HR 1.710, 95% CI 1.244–2.351, PRS ‐ APOE : HR 1.429, 95% CI 1.182–1.728) than APOE ε4 carriers in MCI (PRS + APOE : HR 1.167, 95% CI 1.005–1.355, PRS ‐ APOE : HR 1.172, 95% CI 1.020–1.346) (Table 1 and Figure 1). Gene set enrichment analysis identified 27 significant pathways including those linked to amyloid, lipid, and protein metabolisms (Figure 2). Conclusion The results demonstrated that PRSs showed a significant interaction with APOE ε4 carrier status and PRSs including and excluding APOE regions could predict conversion of MCI to dementia with a stronger association in APOE ε4 non‐carriers than APOE ε4 carriers. This indicates PRS as a potential genetic predictor particularly for progression of MCI patients with no APOE ε4 alleles.